Jekovit D3 (Colecalciferol)

Colecalciferol is converted first in the liver to 25‑hydroxyvitamin D and then in the kidneys to the active hormone 1,25‑dihydroxyvitamin D. This active form binds to the vitamin D receptor, enhancing intestinal absorption of calcium and phosphate, which are essential for bone mineralization and maintenance.

The appropriate dose of Jekovit D3 is determined by a qualified healthcare professional based on the individual’s serum vitamin D level, age, weight, and clinical condition. Patients should follow the prescriber’s instructions and not self‑adjust the dosage.

Safety data for colecalciferol in pregnancy and lactation are limited. It should only be used during pregnancy or while breastfeeding if the prescriber judges that the potential benefit outweighs any possible risk to the mother or infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jekovit D3 provides colecalciferol, the natural form of vitamin D3, which is generally preferred over vitamin D2 (ergocalciferol) because it has a longer half‑life and more efficiently raises serum 25‑hydroxyvitamin D levels. Its efficacy is comparable to other high‑quality vitamin D3 supplements when dosed appropriately.

Store Jekovit D3 at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Jekovit D3 is taken orally, usually with a glass of water. It can be taken with or without food, but consistent administration with meals may improve absorption of the fat‑soluble vitamin.

The most serious risk is hypercalcemia, which can cause kidney stones, cardiac arrhythmias, or calcification of soft tissues. Rarely, severe allergic reactions such as anaphylaxis may occur. Patients should report any symptoms of high calcium levels or allergic response to their healthcare provider promptly.

Individuals with known hypersensitivity to colecalciferol or any excipients, patients with existing hypercalcemia, and those with certain granulomatous diseases (e.g., sarcoidosis) should avoid using Jekovit D3 unless directed otherwise by a qualified clinician.